This clinical trial is focused on studying the effects of a medication called Povorcitinib on a skin condition known as Prurigo Nodularis. Prurigo Nodularis is a chronic skin disease characterized by itchy nodules or bumps on the skin. The purpose of the study is to evaluate how well Povorcitinib can reduce itchiness and improve skin lesions in individuals with this condition.

Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The treatment will be administered in the form of tablets taken orally, and the study will last for a period of up to 48 weeks.

Throughout the study, participants will be monitored to assess the effectiveness and safety of Povorcitinib. The main goal is to see if there is a significant improvement in the itchiness and appearance of the skin lesions by the end of the study period. Participants will have regular check-ups to track their progress and any changes in their condition.